US LiquiBand® distribution agreements signed
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your AMS notes
New US route-to-market strategy now operational and expected to accelerate the growth of LiquiBand® in the US from Q4 2023
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, today announces that its new US LiquiBand® route-to-market strategy is fully operational following the successful signing of all three hospital distribution agreements.
The structure of each of these five-year agreements has been designed to accelerate market share gains and build on the underlying momentum already established by AMS and its partners in this growing $270 million market. This new strategy will enable more product and brand differentiation that will be further strengthened following the expected approval of the Connexicon range in 2024.
Furthermore, the new route-to-market strategy has established a stronger marketing platform to enable the recently launched LiquiBand® XL to gain traction in the US market through all three distribution channels and to build on the success that the product has already achieved, further accelerating overall LiquiBand® growth.
The company can confirm that each of our partners have now completed the transition to the new agreements and throughout the transition, end-user sales have not been affected and there has been no impact on customers. In addition, normal order patterns have resumed for all three partners.
Chris Meredith, Chief Executive Officer of AMS, commented: "The successful signing of all three US distribution agreements is a significant step forward for the Group and marks an important inflection point for the growth of the LiquiBand® portfolio. We are extremely proud of what we have achieved to date in the US, having secured over 20 per cent of the available market. This strengthened route-to-market strategy now provides greater opportunities for us and is an important step in our ambition to more than double market share in the medium term. I look forward to building even stronger and more productive relationships with all our partners as we embark on this next phase of the LiquiBand growth story."
| ICR Consilium | Tel: +44 (0) 20 3709 5700 |
| Matthew Neal / Lucy Featherstone | |
| Investec Bank PLC (NOMAD & Broker) | Tel: +44 (0) 20 7597 5970 |
| Gary Clarence / David Anderson | |
| HSBC Bank PLC (Broker) | Tel: +44 (0) 20 7991 8888 |
Sam McLennan / Joe Weaving / Stephanie Cornish
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.